Active Stocks
Thu Mar 28 2024 14:49:26
  1. Tata Steel share price
  2. 155.95 2.03%
  1. HDFC Bank share price
  2. 1,455.55 1.03%
  1. ITC share price
  2. 430.95 0.69%
  1. Power Grid Corporation Of India share price
  2. 278.75 2.84%
  1. State Bank Of India share price
  2. 756.00 2.99%
Business News/ News / India/  Coronavirus: Sun Pharma to test pancreatitis drug in COVID-19 patients in India
BackBack

Coronavirus: Sun Pharma to test pancreatitis drug in COVID-19 patients in India

Sun Pharma said the pancreatitis drug, nafamostat mesilate, has been identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany

Sun Pharma joins other Indian drugmakers Glenmark Pharmaceuticals and Strides Pharma Science that are conducting trials in India for potential drugs for COVID-19, which currently has no approved treatment or vaccinePremium
Sun Pharma joins other Indian drugmakers Glenmark Pharmaceuticals and Strides Pharma Science that are conducting trials in India for potential drugs for COVID-19, which currently has no approved treatment or vaccine

BENGALURU : Drugmaker Sun Pharmaceutical Industries Ltd said on Friday it has received Indian regulatory approval to start clinical trials of a pancreatitis drug in COVID-19 patients.

The company joins other Indian drugmakers Glenmark Pharmaceuticals Ltd and Strides Pharma Science Ltd that are conducting trials in India for potential drugs for COVID-19, which currently has no approved treatment or vaccine.

Sun Pharma said the pancreatitis drug, nafamostat mesilate, has been "identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany".

The company said it has initiated manufacturing of the active pharmaceutical ingredient (API) and the finished product of the drug using technology from its unit, Pola Pharma Japan.

In April, the University of Tokyo announced plans for a trial of nafamostat mesilate and camostat mesilate, a related drug, licensed in Japan and South Korea to treat chronic pancreatitis.

Sun Pharma shares gained after the announcement, and closed up 3.3% at 474.25 rupees. Shares in Indian drugmakers have been on a tear this year, with the Nifty pharma index rising 21.5% so far.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 29 May 2020, 05:49 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App